Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

It's probably safe to say that weight-loss drugs aren't going anywhere any time soon. According to the most recent data, six percent of American adults, or roughly 16 million people, take such ...

Mounjaro's launch of a weight-loss drug has sparked interest amongst the people of India despite the high price. Experts believe that making the drug locally available would help to reduce the black ...

HYDERABAD: The India launch of Eli Lilly’s popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its availability, with some Indian doctors fielding hundreds of calls ...

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

A new study has found that the weight-loss drug tirzepatide can help people lose a significant amount of weight and keep it ...

Pfizer PFE announced that it is discontinuing the development of danuglipron, its investigational oral GLP-1 receptor agonist (GLP-1 RA), which is being developed to treat obesity. The decision ...

The FDA and the manufacturer of Ozempic, Novo Nordisk are urging patients, doctors and pharmacies to check their Ozempic ...

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its ...

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury.